European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention – 2022 update

Table 3 Randomized placebo-controlled phase II and III clinical trials in individuals with episodic migraine

Drug/Trial	Phase	Dose	Duration	№ of participants
Eptinezumab
PROMISE-1 NCT02559895 [21]	III	100 mg (q) 300 mg (q)	12 weeks	674
Erenumab
NCT01952574 [16]	II	70 mg (m) 140 mg (m)	12 weeks	267
NCT02630459 [25]	II	70 mg (m) 140 mg (m)	12 weeks	475
STRIVE NCT02456740 [24]	III	70 mg (m) 140 mg (m)	24 weeks	955
ARISE NCT02483585 [7]	III	70 mg (m)	12 weeks	577
EMPOwER NCT03333109 [26]	III	70 mg (m) 140 mg (m)	12 weeks	900
NCT03812224 [29]	III	70 mg (m)	24 weeks	261
LIBERTY NCT03096834 [15]	IIIb	140 mg (m)	12-weeks	246
Fremanezumab
NCT02025556 [18]	II	225 mg (m) 675 mg (m)	12 weeks	297
HALO EM NCT02629861 [12]	III	225 mg (m) 675 mg (q)	12 weeks	875
NCT03303092 [28]	III	225 mg (m) 675 mg (q)	12 weeks	357
FOCUS NCT03308968 [11]	IIIb	225 mg (m) 675 mg (q)	12 weeks	329
Galcanezumab^a
EVOLVE-1 NCT02614183 [10]	III	120 mg (m + 240 mg ld)	24 weeks	646
EVOLVE-2 NCT02614196 [9]	III	120 mg (m + 240 mg ld)	24 weeks	692
CONQUER NCT03559257 [8]	IIIb	120 mg (m + 240 mg ld)	12 weeks	269

Duration of all the studies is expressed in weeks and transformed as appropriate from the original study
(m) indicates monthly, (q) indicates quarterly, ld indicates loading dose
^aPhase II trial NCT02163993 [30] tested a 120 mg monthly dose of galcanezumab without loading dose; therefore, it was excluded and not merged with results of other trials using a loading dose

ISSN: 1129-2377